NASDAQ:IRWD Ironwood Pharmaceuticals Q2 2025 Earnings Report $3.64 0.00 (0.00%) Closing price 10/2/2026 04:00 PM EasternExtended Trading$3.67 +0.03 (+0.85%) As of 05:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Ironwood Pharmaceuticals EPS ResultsActual EPS$0.14Consensus EPS -$0.02Beat/MissBeat by +$0.16One Year Ago EPSN/AIronwood Pharmaceuticals Revenue ResultsActual Revenue$85.24 millionExpected Revenue$62.02 millionBeat/MissBeat by +$23.22 millionYoY Revenue GrowthN/AIronwood Pharmaceuticals Announcement DetailsQuarterQ2 2025Date8/7/2025TimeBefore Market OpensConference Call DateThursday, August 7, 2025Conference Call Time7:00AM ETUpcoming EarningsIronwood Pharmaceuticals' Q3 2026 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Ironwood Pharmaceuticals Earnings HeadlinesIronwood Pharmaceuticals (NASDAQ:IRWD) Upgraded at Jefferies Financial GroupSeptember 28, 2026 | americanbankingnews.comIronwood Pharmaceuticals (NASDAQ:IRWD) Shares Break Above 200 Day Moving Average - Time to Sell?September 26, 2026 | americanbankingnews.comIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country. | Banyan Hill Publishing (Ad)Ironwood Pharmaceuticals, Inc. (IRWD)September 23, 2026 | finance.yahoo.comIronwood: Medicare Is Not The Problem I Thought It WasSeptember 11, 2026 | seekingalpha.comIronwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare ConferenceSeptember 3, 2026 | businesswire.comSee More Ironwood Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Ironwood Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ironwood Pharmaceuticals and other key companies, straight to your email. Email Address About Ironwood PharmaceuticalsIronwood Pharmaceuticals (NASDAQ:IRWD) is a gastrointestinal-focused biopharmaceutical company that discovers, develops, and commercializes medicines for gastrointestinal diseases. The company concentrates on conditions affecting the digestive system, including disorders with substantial unmet medical needs. Ironwood’s principal commercial product is LINZESS (linaclotide), a prescription treatment for adults with irritable bowel syndrome with constipation and chronic idiopathic constipation. In the United States, LINZESS is marketed through a collaboration with AbbVie, while it is marketed in many international markets under the name CONSTELLA through a collaboration with the healthcare business of AstraZeneca and other regional partners. Founded in 1998 and headquartered in Boston, Massachusetts, Ironwood has expanded its development activities through internal research, partnerships, and acquisitions. The company’s pipeline has included additional therapies for gastrointestinal and related disorders, including programs obtained through its acquisition of VectivBio. Ironwood’s products and development programs serve patients in the United States and selected international markets through its commercial operations and collaboration network. Tom McCourt serves as the company’s chief executive officer.View Ironwood Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/28 - 10/02Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam?Time to Nibble on MCD Stock After it Enters Oversold Territory?Liberty Energy’s AI Power Push Has Wall Street DividedMcCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the Test Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
